Optimi Health Ships First Psilocybin to UK for Phase 2 Trial

Optimi Health Corp., a commercial-stage pharmaceutical company focused on manufacturing and distributing GMP-grade psychedelic drug products for mental health therapies, has announced the completion of its first export of naturally derived psilocybin to the United Kingdom. The shipment, which includes psilocybin biomass and finished 5 mg psilocybin capsules, was manufactured at the company's GMP facility in Princeton, British Columbia. This export supports a planned Phase 2 clinical trial and was authorized by Health Canada and the UK Home Office. The capsules use the same formulation currently prescribed to patients in Australia for treatment-resistant depression, reinforcing Optimi's position as a vertically integrated GMP supplier serving both regulated patient access programs and clinical research initiatives.

Optimi Health (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) is a Health Canada-licensed pharmaceutical manufacturer that produces validated MDMA and botanical psilocybin drug products. The company supplies active pharmaceutical ingredients and finished dosage forms to regulated clinical and therapeutic programs internationally. Products are currently prescribed to patients in Australia under the country's Authorized Prescriber Scheme and accessible in Canada through the Special Access Program. This export marks a significant step in expanding access to psilocybin-based therapies for mental health conditions, particularly treatment-resistant depression.

The news was disseminated through InvestorWire, a specialized communications platform and part of the Dynamic Brand Portfolio @ IBN. InvestorWire provides wire-grade press release syndication and editorial syndication to 5,000+ outlets, enhancing visibility for companies like Optimi. For the full press release, visit https://ibn.fm/WLDHZ. More information about Optimi can be found at optimi.net.